Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study

Su Mi Lee, Mi Yeun Han, Su Hyun Kim, Ran Hui Cha, Seock Hui Kang, Jun Chul Kim, Won Suk An, Su Mi Lee, Mi Yeun Han, Su Hyun Kim, Ran Hui Cha, Seock Hui Kang, Jun Chul Kim, Won Suk An

Abstract

Serum myostatin and indoxyl sulfate (IS) levels increase with kidney function decline and may function as uremic toxins in chronic kidney disease (CKD)-related sarcopenia. Herein, we analyzed the association between serum myostatin and IS levels and sarcopenia in patients with CKD, by performing a post hoc analysis of baseline data extracted from the RECOVERY study (clinicaltrials.gov: NCT03788252) of 150 patients with CKD. We stratified patients into two groups according to the median value of myostatin (cutoff 4.5 ng/mL) and IS levels (cutoff 0.365 mg/dL). The proportion of patients with sarcopenia was higher in those with high IS levels but lower in those with high myostatin levels. The skeletal muscle mass index (SMI) and handgrip strength (HGS) were significantly lower in patients with high IS levels but significantly higher in patients with high myostatin levels. IS levels showed a negative correlation with glomerular filtration rate (GFR), SMI, and HGS. However, myostatin levels were positively correlated with SMI and HGS, but not with GFR. Sarcopenia was independently associated with age and IS level after adjustment. Increased levels of serum total IS might play a role in sarcopenia, while increased levels of serum myostatin are associated with muscle mass in patients with CKD.

Keywords: chronic kidney disease; indoxyl sulfate; myostatin; sarcopenia.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Receiver operating characteristic curve of IS levels for predicting the probability of presarcopenia (A) and sarcopenia (B).

References

    1. Lai S., Muscaritoli M., Andreozzi P., Sgreccia A., De Leo S., Mazzaferro S., Mitterhofer A.P., Pasquali M., Protopapa P., Spagnoli A., et al. Sarcopenia and cardiovascular risk indices in patients with chronic kidney disease on conservative and replacement therapy. Nutrition. 2019;62:108–114. doi: 10.1016/j.nut.2018.12.005.
    1. Pereira R.A., Cordeiro A.C., Avesani C.M., Carrero J.J., Lindholm B., Amparo F.C., Amodeo C., Cuppari L., Kamimura M.A. Sarcopenia in chronic kidney disease on conservative therapy: Prevalence and association with mortality. Nephrol. Dial. Transplant. 2015;30:1718–1725. doi: 10.1093/ndt/gfv133.
    1. Enoki Y., Watanabe H., Arake R., Sugimoto R., Imafuku T., Tominaga Y., Ishima Y., Kotani S., Nakajima M., Tanaka M., et al. Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1. Sci. Rep. 2016;6:32084. doi: 10.1038/srep32084.
    1. Bataille S., Dou L., Bartoli M., Sallee M., Aniort J., Ferkak B., Chermiti R., McKay N., Da Silva N., Burtey S., et al. Mechanisms of myostatin and activin A accumulation in chronic kidney disease. Nephrol. Dial. Transplant. 2022;37:1249–1260. doi: 10.1093/ndt/gfac136.
    1. Yano S., Nagai A., Isomura M., Yamasaki M., Kijima T., Takeda M., Hamano T., Nabika T. Relationship between Blood Myostatin Levels and Kidney Function: Shimane CoHRE Study. PLoS ONE. 2015;10:e0141035. doi: 10.1371/journal.pone.0141035.
    1. Holle J., Querfeld U., Kirchner M., Anninos A., Okun J., Thurn-Valsassina D., Bayazit A., Niemirska A., Canpolat N., Bulut I.K., et al. Indoxyl sulfate associates with cardiovascular phenotype in children with chronic kidney disease. Pediatr. Nephrol. 2019;34:2571–2582. doi: 10.1007/s00467-019-04331-6.
    1. Choi S.J., Lee M.S., Kang D.H., Ko G.J., Lim H.S., Yu B.C., Park M.Y., Kim J.K., Kim C.H., Hwang S.D., et al. Myostatin/Appendicular Skeletal Muscle Mass (ASM) Ratio, Not Myostatin, Is Associated with Low Handgrip Strength in Community-Dwelling Older Women. Int. J. Environ. Res. Public Health. 2021;18:7344. doi: 10.3390/ijerph18147344.
    1. Barreto F.C., Barreto D.V., Liabeuf S., Meert N., Glorieux G., Temmar M., Choukroun G., Vanholder R., Massy Z.A., European Uremic Toxin Work Group (EUTox) Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin. J. Am. Soc. Nephrol. 2009;4:1551–1558. doi: 10.2215/CJN.03980609.
    1. Cheng T.C., Huang S.H., Kao C.L., Hsu P.C. Muscle Wasting in Chronic Kidney Disease: Mechanism and Clinical Implications—A Narrative Review. Int. J. Mol. Sci. 2022;23:6047. doi: 10.3390/ijms23116047.
    1. McPherron A.C., Lawler A.M., Lee S.J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387:83–90. doi: 10.1038/387083a0.
    1. Zimmers T.A., Davies M.V., Koniaris L.G., Haynes P., Esquela A.F., Tomkinson K.N., McPherron A.C., Wolfman N.M., Lee S.J. Induction of cachexia in mice by systemically administered myostatin. Science. 2002;296:1486–1488. doi: 10.1126/science.1069525.
    1. Schuelke M., Wagner K.R., Stolz L.E., Hubner C., Riebel T., Komen W., Braun T., Tobin J.F., Lee S.J. Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. 2004;350:2682–2688. doi: 10.1056/NEJMoa040933.
    1. Ju C.R., Chen R.C. Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease. Respir. Med. 2012;106:102–108. doi: 10.1016/j.rmed.2011.07.016.
    1. George I., Bish L.T., Kamalakkannan G., Petrilli C.M., Oz M.C., Naka Y., Sweeney H.L., Maybaum S. Myostatin activation in patients with advanced heart failure and after mechanical unloading. Eur. J. Heart Fail. 2010;12:444–453. doi: 10.1093/eurjhf/hfq039.
    1. Kopple J.D., Cohen A.H., Wang H., Qing D., Tang Z., Fournier M., Lewis M., Casaburi R., Storer T. Effect of exercise on mRNA levels for growth factors in skeletal muscle of hemodialysis patients. J. Ren. Nutr. 2006;16:312–324. doi: 10.1053/j.jrn.2006.04.028.
    1. Han D.S., Chen Y.M., Lin S.Y., Chang H.H., Huang T.M., Chi Y.C., Yang W.S. Serum myostatin levels and grip strength in normal subjects and patients on maintenance haemodialysis. Clin. Endocrinol. 2011;75:857–863. doi: 10.1111/j.1365-2265.2011.04120.x.
    1. Yamada S., Tsuruya K., Yoshida H., Tokumoto M., Ueki K., Ooboshi H., Kitazono T. Factors Associated with the Serum Myostatin Level in Patients Undergoing Peritoneal Dialysis: Potential Effects of Skeletal Muscle Mass and Vitamin D Receptor Activator Use. Calcif. Tissue Int. 2016;99:13–22. doi: 10.1007/s00223-016-0118-6.
    1. Lee S.M., Kim S.E., Lee J.Y., Jeong H.J., Son Y.K., An W.S. Serum myostatin levels are associated with abdominal aortic calcification in dialysis patients. Kidney Res. Clin. Pract. 2019;38:481–489. doi: 10.23876/j.krcp.19.019.
    1. Willoughby D.S. Effects of heavy resistance training on myostatin mRNA and protein expression. Med. Sci. Sports Exerc. 2004;36:574–582. doi: 10.1249/01.MSS.0000121952.71533.EA.
    1. Cha R.H., Kang S.H., Han M.Y., An W.S., Kim S.H., Kim J.C. Effects of AST-120 on muscle health and quality of life in chronic kidney disease patients: Results of RECOVERY study. J. Cachexia Sarcopenia Muscle. 2021;13:397–408. doi: 10.1002/jcsm.12874.
    1. Shin J., Hwang J.H., Han M., Cha R.H., Kang S.H., An W.S., Kim J.C., Kim S.H. Phase angle as a marker for muscle health and quality of life in patients with chronic kidney disease. Clin. Nutr. 2022;41:1651–1659. doi: 10.1016/j.clnu.2022.06.009.
    1. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., 3rd, Feldman H.I., Kusek J.W., Eggers P., Van Lente F., Greene T., et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 2009;150:604–612. doi: 10.7326/0003-4819-150-9-200905050-00006.
    1. Charlson M., Szatrowski T.P., Peterson J., Gold J. Validation of a combined comorbidity index. J. Clin. Epidemiol. 1994;47:1245–1251. doi: 10.1016/0895-4356(94)90129-5.
    1. Chen L.K., Woo J., Assantachai P., Auyeung T.W., Chou M.Y., Iijima K., Jang H.C., Kang L., Kim M., Kim S., et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J. Am. Med. Dir. Assoc. 2020;21:300–307.e2. doi: 10.1016/j.jamda.2019.12.012.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir